Canada
Puerto Rico
USA
Belgium
France
UK
IndiaAcross pharma organizations, a persistent challenge is visible across Clinical Operations and Patient Engagement functions.
Clinical trials do not struggle because we lack data. They struggle because execution breaks down across the patient journey.
They struggle because we don’t know how to consistently use the data we already have.
Patient records, eligibility data, site information, engagement logs, and operational documents exist across pharma organizations today. Much of it sits in unstructured formats, siloed systems, or legacy platforms. Clinical Ops leaders know this data matters, but turning it into timely, repeatable decisions that improve recruitment and retention remains difficult.
This is where the conversation needs to change.
The Patient Journey Problem Begins Long Before the Trial
For many patients, especially with rare diseases, the path to a clinical trial is already long, fragmented, and emotionally exhausting.
- Spend 5 years or more seeking a correct diagnosis
- Visit multiple physicians and specialists
- Undergo repeated testing and misdiagnoses
- Physical fatigue
- Financial and caregiver burden
- Mistrust, fear, and confusion
The State of Clinical Trials Today: Operational Friction Everywhere
From a systems and process perspective, the state of clinical trials remains highly manual and fragmented.
- Patients search through thousands of trials on their own
- Eligibility verification requires manual data consolidation across providers
- Enrollment and screening take weeks, sometimes months
- Adherence relies on patient memory, diaries, and infrequent site visits
Nearly 30% of Phase 3 trials
fail due to enrollment challenges
Recruitment delays cost sponsors
millions of dollars per trial
This is not due to lack of clinical excellence: it is due to lack of connected, patient‑aware execution.
Rare Diseases Make the Challenge Exponentially Harder
Rare diseases magnify every weakness in the trial ecosystem.
Rare diseases affect
~30 million people
The average time to
diagnosis is 3.9–5 years
Patients often face unexpected financial strain and debt during their diagnostic journey
Recruitment is further complicated by:
- Small, geographically dispersed populations
- Pediatric prevalence in over 50% of rare diseases
- Low disease awareness and limited specialist access
Traditional site centric recruitment models simply do not scale in this reality.
The Real Issue Isn’t Technology: It’s Data Usability
- Patient records and claims data
- Trial eligibility criteria
- Engagement data
- Operational and site‑level information
- Unstructured formats (documents, PDFs, narratives)
- Disconnected platforms
- Legacy systems that do not talk to each other
AI plays a critical role here, but not in the way it is often marketed.
Research consistently shows that data fragmentation and lack of integration are major contributors to recruitment delays and participant drop‑off, even in well‑funded trials.
The Role of AI: Turning Fragmented Data Into Usable Signals
From an IT leadership perspective, AI’s most valuable contribution today is not autonomy—it’s translation.
AI enables us to:
- Extract meaning from unstructured data sources
- Normalize and connect fragmented datasets
- Map clinical eligibility with SDoH context
- Surface early signals of disengagement
In practical terms, AI turns unusable data into usable inputs for Clinical Ops and Patient Engagement teams.
Recent studies reinforce that AI’s near‑term value in clinical trials lies in data harmonization and insight generation, rather than decision automation.
But even usable data-based signals alone are not enough.
Why Social Determinants of Health Were Underused for So Long
Research has long shown that trial participation is shaped by various Social Determinants of Health (SDOH):
- Transportation access
- Food security
- Financial stress
- Trust and fear of side effects
- Time and caregiver burden
Until recently, these factors, captured under SDoH and behavioral motivation research, were well understood academically.
What was missing was:
- A way to integrate them with clinical data
- A framework to act on them consistently
- Automation to scale responses across trials
As a result, SDoH insights remained largely academic, despite strong evidence that they directly affect recruitment, retention, and adherence.
Bridging Insight and Execution with a Motivation Based Framework
Behavioral research has long identified the factors that influence trial participation: motivation, fear, trust, perceived effort, and personal constraints. These insights are well documented in peer‑reviewed literature.
What’s been missing is the ability to embed this research into operational workflows.
This is where a technology‑led, framework‑driven approach becomes essential.
At Innova Solutions, the focus has been on building a structured framework grounded in validated motivational research, combined with AI and automation, to support execution, not just analysis.
Key elements include:
- Mapping patient data with SDoH indicators (financial stress, transport, food, health status etc.)
- Identifying top motivation and fear factors for each participant
- Enabling next‑best actions such as:
- Appointment scheduling
- Targeted reminders
- Transportation or support services
- Educational or advocacy resources
The framework ensures insights lead to consistent, human‑centered action.
This approach is not about collecting new data. It is about finally using existing data from pharma organizations in a way that supports real‑world trial execution.
Designing Engagement Around the Real Patient Journey
A framework only works if it aligns with how patients actually move through trials.
That means supporting:
- Pre‑screening and education
- Advocacy group engagement
- Site‑specific recruitment strategies
- Ongoing participation and retention
When engagement is aligned to patient context rather than generic workflows, participation becomes sustainable rather than fragile.
Measurable Outcomes That Matter to Clinical Ops Leaders
When data usability, SDoH context, and motivation based frameworks come together, the outcomes are tangible:
- More precise & faster recruitment without expanding site burden
- Earlier identification of retention risks
- Engagement strategies aligned to real patient constraints
- Improved diversity through context‑aware participation
- Improved retention and adherence
- Better use of decentralized and hybrid trial models
- Reduced drop‑offs, trial delays, & operational friction
- Time and cost savings across the trial lifecycle
Evidence increasingly supports that participant centric, context driven approaches lead to stronger trial performance and more reliable outcomes
From IT Enablement to Execution Leadership
From my perspective, the future of clinical trials will not be defined by who adopts AI first.
It will be defined by who:
- Makes fragmented data usable
- Understands the human realities behind participation
- Applies a structured framework to act on insights—consistently and at scale
The real responsibility of clinical operations and patient engagement leaders is no longer limited to enabling systems.
It is to help operations and engagement teams execute better decisions, faster, across the entire patient journey.
Clinical trials succeed when technology aligns with human reality.
That is where real innovation begins.
